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A B S T R A C T
Background
Dental pain can have a considerable detrimental effect on an individual’s quality of life. Symptomatic apical periodontitis and acute
apical abscess are common causes of dental pain and arise from an inflamed or necrotic dental pulp, or infection of the pulpless root
canal system. Clinical guidelines recommend that the first-line treatment for teeth with symptomatic apical periodontitis or an acute
apical abscess should be removal of the source of inflammation or infection by local, operative measures, and that systemic antibiotics are
currently only recommended for situations where there is evidence of spreading infection (cellulitis, lymph node involvement, diffuse
swelling) or systemic involvement (fever, malaise). Despite this, there is evidence that dentists continue to prescribe antibiotics for these
conditions. There is concern that this could contribute to the development of antibiotic-resistant bacterial colonies both within the
individual and within the community as a whole.
Objectives
To evaluate the effects of systemic antibiotics provided with or without surgical intervention (such as extraction, incision and drainage
of a swelling or endodontic treatment), with or without analgesics, for symptomatic apical periodontitis or acute apical abscess in adults.
Search methods
We searched the following electronic databases: Cochrane Oral Health Group’s Trials Register (to 1 October 2013); Cochrane Central
Register of Controlled Trials (The Cochrane Library 2013, Issue 9); MEDLINE via OVID (1946 to 1 October 2013); EMBASE via
OVID (1980 to 1 October 2013) and CINAHL via EBSCO (1980 to 1 October 2013). We searched the World Health Organization
(WHO) International Trials Registry Platform and the US National Institutes of Health Trials Registry (ClinicalTrials.gov) on 1
October 2013 to identify ongoing trials. We searched for grey literature using OpenGrey (to 1 October 2013) and ZETOCConference
Proceedings (1993 to 1 October 2013). We placed no restrictions on the language or date of publication when searching the electronic
databases.
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Selection criteria
Randomised controlled trials of systemic antibiotics in adults with a clinical diagnosis of symptomatic apical periodontitis or acute
apical abscess, with or without surgical intervention (considered in this situation to be extraction, incision and drainage or endodontic
treatment) and with or without analgesics.
Data collection and analysis
Two review authors screened the results of the searches against inclusion criteria, extracted data and assessed risk of bias independently
and in duplicate. We calculated mean differences (MD) (standardised mean difference (SMD) when different scales were reported) and
95% confidence intervals (CI) for continuous data and, where results were meta-analysed, we used a fixed-effect model as there were
fewer than four studies. We contacted study authors to obtain missing information.
Main results
We included two trials in this review, with 62 participants included in the analyses. Both trials were conducted in university dental
schools in theUSA and compared the effects of oral penicillinV potassium (penicillinVK) versus amatched placebo given in conjunction
with a surgical intervention (total or partial pulpectomy) and analgesics to adults with acute apical abscess or symptomatic necrotic
tooth (no signs of spreading infection or systemic involvement (fever, malaise)). We assessed one study as having a high risk of bias and
the other study as having unclear risk of bias.
The primary outcome variables presented were participant-reported pain and swelling (one trial also reported participant-reported
percussion pain). One study reported the type and number of analgesics taken by participants. One study recorded the incidence
of postoperative endodontic flare-ups (people who returned with symptoms that necessitated further treatment). Adverse effects as
reported in one study were diarrhoea (one participant, placebo group) and fatigue and reduced energy postoperatively (one participant,
antibiotic group). No studies reporting quality of life measurements were suitable for inclusion.
Objective 1: systemic antibiotics versus placebo with surgical intervention and analgesics for symptomatic apical periodontitis
or acute apical abscess.
Two studies provided data for the comparison between systemic antibiotics (penicillin VK) and a matched placebo for adults with
acute apical abscess or a symptomatic necrotic tooth. Participants in one study all underwent a total pulpectomy of the affected tooth
while participants in the other study had their tooth treated by either partial or total pulpectomy. Participants in both trials received
oral analgesics. There were no statistically significant differences in participant-reported measures of pain or swelling at any of the time
points assessed within the review. The MD for pain (short ordinal numerical scale 0 to 3) was -0.03 (95% CI -0.53 to 0.47) at 24
hours; 0.32 (95% CI -0.22 to 0.86) at 48 hours and 0.08 (95% CI -0.38 to 0.54) at 72 hours. The SMD for swelling was 0.27 (95%
CI -0.23 to 0.78) at 24 hours; 0.04 (95% CI -0.47 to 0.55) at 48 hours and 0.02 (95% CI -0.49 to 0.52) at 72 hours. The body of
evidence was assessed as at very low quality.
Objective 2: systemic antibiotics without surgical intervention for adults with symptomatic apical periodontitis or acute apical
abscess.
We found no studies that compared the effects of systemic antibiotics with a matched placebo delivered without a surgical intervention
for symptomatic apical periodontitis or acute apical abscess in adults.
Authors’ conclusions
There is very low quality evidence that is insufficient to determine the effects of systemic antibiotics on adults with symptomatic apical
periodontitis or acute apical abscess.
P L A I N L A N G U A G E S U M M A R Y
The effects of antibiotics on toothache caused by inflammation or infection at the root of the tooth in adults
This review, carried out by authors of the Cochrane Oral Health Group, has been produced to assess the effects of antibiotics on pain
and swelling in two conditions commonly responsible for causing dental pain when given with or without dental treatment (such as
extraction, drainage of a swelling or root canal treatment).
Background
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Dental pain is a common problem and can arise when the nerve within a tooth dies due to progressing decay or severe trauma. The
tissue around the end of the root then becomes inflamed and this can lead to acute pain, which gets worse on biting. Without treatment,
bacteria can infect the dead tooth and cause a dental abscess, which can lead to swelling and spreading infection that may be life
threatening.
The recommended treatment of this form of toothache is the removal the dead nerve and associated bacteria. This is usually done by
dental extraction or root canal treatment. Antibiotics should only be prescribed when there is severe infection that has spread from
the tooth. However, some dentists still routinely prescribe oral antibiotics to people with acute dental conditions that have no signs of
spreading infection.
Minimising inappropriate antibiotic prescribing is plays a key role in limiting the development of antibiotic-resistant bacteria. Since
dentists prescribe approximately 8% to 10% of all primary care antibiotics in developed countries, dental prescribing may contribute
to antibiotic resistance. Therefore, it is important that antibiotics should only be used when they are clinically beneficial for the person.
Study characteristics
The evidence on which this review is based was up to date as of 1 October 2013. We searched scientific databases and found two trials,
with a 62 participants included in the analysis. Both trials were conducted at university dental schools in the USA and evaluated the
use of oral antibiotics in the reduction of pain and swelling reported by adults after having the first stage of root canal treatment under
local anaesthetic. The antibiotic used in both trials was penicillin VK and all participants also received painkillers.
Key results
The two studies included in the review reported that there were no clear differences in the pain or swelling reported by participants
who received oral antibiotics compared with a placebo (a dummy treatment) when provided in conjunction with the first stage of root
canal treatment and painkillers, but the studies were small and we could not exclude potentially important differences between groups.
Neither study examined the effect of antibiotics delivered by themselves, without dental treatment.
One trial reported side effects among participants: one person who received the placebo medication had diarrhoea and one person who
received antibiotics experienced tiredness and reduced energy after their operation.
Quality of evidence
We judged the quality of evidence to be very low. There is currently insufficient evidence to be able to determine the effects of antibiotics
in these conditions.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Systemic antibiotics with a surgical intervention and analgesics for the management of symptomatic apical periodontitis and acute apical abscess in adults
Patient or population: adults with a symptomatic necrotic tooth or localised acute apical abscess (no signs of spreading infection or systemic involvement)
Settings: university dental schools, USA
Intervention: systemic antibiotics, partial or total pulpectomy and analgesics
Comparison: matched placebo, partial or total pulpectomy and analgesics
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Matched placebo, par-
tial or total pulpectomy
and analgesics
Sys-
temic antibiotics, partial
or total pulpectomy and
analgesics
Pain at 24 hours
Short ordinal numerical
scale. Scale from: 0 to 3
The mean pain at 24
hours ranged across con-
trol groups from:
1.0 to 1.68
The mean pain at 24
hours in the intervention
groups was
0.03 lower
(0.53 lower to 0.47
higher)
- 61
(2 studies)
⊕©©©
very low1,2,3
-
Pain at 48 hours
Short ordinal numerical
scale. Scale from: 0 to 3
The mean pain at 48
hours ranged across con-
trol groups from:
0.8 to 0.95
The mean pain at 48
hours in the intervention
groups was
0.32 higher
(0.22 lower to 0.86
higher)
- 61
(2 studies)
⊕©©©
very low1,2,3
-
Pain at 72 hours
Short ordinal scale. Scale
from: 0 to 3
The mean pain at 72
hours ranged across con-
trol groups from:
0.3 to 0.82
The mean pain at 72
hours in the intervention
groups was
0.08 higher
(0.38 lower to 0.54
- 61
(2 studies)
⊕©©©
very low1,2,3
-
4
S
y
ste
m
ic
a
n
tib
io
tic
s
fo
r
sy
m
p
to
m
a
tic
a
p
ic
a
l
p
e
rio
d
o
n
titis
a
n
d
a
c
u
te
a
p
ic
a
l
a
b
sc
e
ss
in
a
d
u
lts
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
4
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
higher)
Swelling at 24 hours
Different short ordinal nu-
merical scales
The mean swelling at
24 hours in the control
groups was
0.59 4
The mean swelling at 24
hours in the intervention
groups was
0.27 standard deviations
higher
(0.23 lower to 0.78
higher)
- 62
(2 studies)
⊕©©©
very low1,2,3
This converts back into
a 36% increase (95% CI
31% decrease to 105%
increase) of control mean
for antibiotics (based on
1 study at unclear risk of
bias)
Swelling at 48 hours
different short ordinal nu-
merical scales
The mean swelling at
48 hours in the control
groups was
0.73 4
The mean swelling at 48
hours in the intervention
groups was
0.04 standard deviations
higher
(0.47 lower to 0.55
higher)
- 61
(2 studies)
⊕©©©
very low1,2,3
This converts back into
a 4% increase (95% CI
49% decrease to 58% in-
crease) of control mean
for antibiotics (based on
1 study at unclear risk of
bias)
Swelling at 72 hours
different short ordinal nu-
merical scales
The mean swelling at
72 hours in the control
groups was
0.59 4
The mean swelling at 72
hours in the intervention
groups was
0.02 standard deviations
higher
(0.49 lower to 0.52
higher)
- 61
(2 studies)
⊕©©©
very low1,2,3
This converts back to into
a 2% increase (95% CI
55% decrease to 59% in-
crease) of control mean
for antibiotics (based on
1 study at unclear risk of
bias)
Adverse effects During the 3-day follow-up period in Fouad 1996, 1 participant in the placebo group reported diarrhoea and 1 participant in the antibiotic group reported fatigue
and reduced energy postoperatively
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.5
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1 One study with high risk of bias and small group sizes.
2One study with unclear risk of bias and small group sizes.
3 Different surgical interventions employed. Participants in one study had partial or total pulpectomy (there was no way of distinguishing
between the two treatment modalities) while participants in the other all had total pulpectomy.
4 Re-expressed from the standardised mean difference into the short ordinal numerical scale used by Henry 2001. Results should be
interpreted with caution since back-translation of the effect size is based on the results of only one study.
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B A C K G R O U N D
Description of the condition
Dental pain can have a considerable detrimental effect on an in-
dividual’s social functioning and quality of life (Reisine 1995; Pau
2005). In the Adult Dental Health Survey of 2009 conducted in
the UK, 29% of individuals reported experiencing dental pain ’oc-
casionally’ or ’fairly/very often’ during the preceding 12 months.
Within the survey, prevalence of dental pain was 9%, with higher
values reported for younger individuals and among lower socioeco-
nomic groups (Steele 2011). Of these individuals, approximately
30% will be have symptomatic apical periodontitis and a fur-
ther 13% will have an acute apical abscess (Sindet-Pedersen 1985;
Estrela 2011).
Apical periodontitis arises following injury to the pulpal tissues of
a tooth due to dental caries, tooth fracture, trauma or iatrogenic
damage.While the dental pulp can recover from reversible pulpitis
resulting from a mild to moderate injury, persistent or extensive
damage results in irreversible levels of inflammation within the
pulpal tissues. Should this occur, peoplemay experience symptoms
of irreversible pulpitis. Without treatment, irreversibly inflamed
teeth then undergo pulpal necrosis and bacterial colonisation of
the root canal system (Abbott 2004; Bergenholtz 2010).
Apical periodontitis (also known as periapical periodontitis) is an
inflammatory lesion of the periradicular tissues that arises princi-
pally due to the egress of irritants such as bacteria and toxins from
an inflamed or necrotic pulp (Torabinejad 1994). Its evolutionary
role is protective: to contain the root canal bacteria and prevent
the spread of infection. While the vast majority of cases are asymp-
tomatic, exacerbations of apical periodontitis can present as symp-
tomatic apical periodontitis or an acute apical abscess (Bergenholtz
2010).
Symptomatic apical periodontitis can arise either from a formerly
healthy tooth that has subsequently undergone pulpal breakdown
or from a tooth with a previously asymptomatic apical periodon-
titis. It is characterised by a dull or throbbing pain that is exacer-
bated by biting. The affected tooth usually has a negative or de-
layed positive response to vitality testing and is often highly sen-
sitive to percussive forces (Bergenholtz 2010).
It should be noted that in determining the health of pulpal tissues,
the term ’vitality testing’ is commonly used. True ’vitality’ tests
attempt to examine the presence of pulp blood flow, while ’sensi-
bility’ tests employ the use of thermal or electrical stimuli to elicit
a response from innervated tissue (Chen 2009). Although neither
can definitively indicate the health of the dental pulp, they remain
useful diagnostic aids, commonly used in both clinical practice
and scientific studies.
Acute apical abscesses develop in the presence of a pre-existing
apical periodontitis (Carrotte 2004). Persistent presence of infec-
tive material within the pulpless root canal system and around the
apex of a tooth can lead to a massive influx of polymorphonuclear
leukocytes into the periradicular tissues, leading to tissue liquefac-
tion and pus formation (Bergenholtz 2010). Also known as a peri-
apical, dentoalveolar or alveolar abscess, an apical abscess is char-
acterised by the accumulation of pus in the periradicular tissues
and can present as either an acute or chronic lesion. People with
acute apical abscesses complain of a rapid onset, spontaneous pain,
tenderness of the tooth to pressure, pus formation and swelling
of associated tissues (Glickman 2009). Left untreated, the abscess
may spread resulting in a serious, potentially life-threatening head
and neck infection accompanied by fever,malaise and lymph node
involvement (Abbott 2004). Since symptomatic apical periodon-
titis and acute apical abscess represent a continuum of the same
disease process, it is appropriate to consider both conditions in
this review (Sutherland 2004).
Description of the intervention
Clinical guidelines recommend that the first-line treatment for
teeth with either symptomatic apical periodontitis or an acute api-
cal abscess is the removal of the source of inflammation or infection
by local, operative measures (Glenny 2004; SDCEP 2011). This
involves either the extraction of the offending tooth, extirpation
(removal) of the pulpal tissues, possibly in combination with the
incision and drainage of any swelling present. Systemic antibiotics
are currently only recommended for situations where there is evi-
dence of spreading infection (cellulitis, lymph node involvement,
diffuse swelling) or systemic symptoms (fever, malaise) (SDCEP
2011; Palmer 2012).
Several studies appear to indicate that antibiotics do not reduce the
pain or swelling arising from teethwith symptomatic apical pathol-
ogy in the absence of evidence of systemic involvement (Fouad
1996; Henry 2001). Nevertheless, 69% of individuals attending
a British out-of-hours dental clinic with symptomatic apical peri-
odontitis received a prescription for systemic antibiotics, many in
the absence of a surgical intervention (Dailey 2001). Furthermore,
the authors of the paper suggested that clinicians providing emer-
gency dental treatment may be prescribing antibiotics as the first-
line treatment for people with dental pain (Dailey 2001). In a sur-
vey of Spanish oral surgeons, over 70% reported that they would
prescribe systemic antibiotics for people with moderate to severe
pre-operative symptoms from a tooth with a necrotic pulp and
acute apical periodontitis (Segura-Egea 2010). Comparatively, in
a survey of members of the American Association of Endodontists,
only 54% of respondents reported that they would prescribe an-
tibiotics for the same condition, highlighting differences between
practitioners of nationalities and specialities (Yingling 2002).
How the intervention might work
Doctors and dentists may prescribe systemic antibiotics to min-
imise the signs and symptoms of symptomatic apical periodontitis
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or acute apical abscess, and to treat or prevent the development
of a serious orofacial swelling with systemic involvement. Antibi-
otics can be prescribed as an adjunctive or stand-alone treatment.
People prescribed antibiotics may be given analgesics at the same
time.
Why it is important to do this review
There is international concern about the overuse of antibiotics
and the emergence of antibiotic-resistant bacterial strains (World
Health Organization 2000). Since approximately 8% to 10% of
antibiotics dispensed in primary care in developed countries are
prescribed by a dentist, it is important not to underestimate the po-
tential contribution of the dental profession to the development of
antibiotic resistance (Al-Haroni 2007;Holyfield 2009; Prescribing
and Primary Care Services 2013). Inappropriate use of antibiotics
not only drives antibiotic resistance and misuses resources, it in-
creases the risk of potentially fatal anaphylactic reactions and ex-
poses people to unnecessary side effects (Gonzales 2001; Costelloe
2010). Furthermore, antibiotic prescribing for common medical
problems increases patient expectations for antibiotics, leading to
a vicious cycle of increased prescribing in order to meet expecta-
tions (Little 1997; Coenen 2006).
If systemic antibiotics are effective in the treatment of symptomatic
apical periodontitis or acute apical abscess then it is important that
the nature of any benefits be quantified. However, if antibiotics
are ineffective, people may be unnecessarily exposed to harmful
side effects and the increased possibility of developing antibiotic-
resistant bacterial colonies. It is important that antibiotics be pre-
scribed for dental conditions only when they are likely to result
in clinical benefit for the person. Therefore, the objective of this
review was to evaluate the effects of systemic antibiotics for symp-
tomatic apical periodontitis and acute apical abscess in adults.
O B J E C T I V E S
To evaluate the effects of systemic antibiotics provided with or
without surgical intervention (such as extraction, incision and
drainage of a swelling or endodontic treatment), with or without
analgesics, for symptomatic apical periodontitis or acute apical ab-
scess in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) with parallel
group design in the review. We excluded cluster RCTs.
Types of participants
Studies of adults (over the age of 18 years), male or female, who
presented with a single tooth with a clinical diagnosis of either
symptomatic apical periodontitis or acute apical abscess.
Types of interventions
Active intervention
Administration of any systemic antibiotic (either oral or intra-
venous) at any dosage prescribed in the symptomatic phase of api-
cal periodontitis or acute apical abscess (with orwithout analgesics,
and with or without surgical intervention (extraction, incision and
drainage or endodontic treatment).
Control
Administration of a matched placebo prescribed in the symp-
tomatic phase of apical periodontitis or acute apical abscess (with
or without analgesics, and with or without surgical intervention).
Types of outcome measures
Primary outcomes
1. Measures of participant-reported pain and swelling, gauged
on either a continuous scale, such as visual analogue scale (VAS),
or using binary or dichotomous outcomes.
2. Clinician-reported measures of infection, such as swelling,
temperature, trismus (reduced mouth opening), regional
lymphadenopathy or cellulitis. These outcomes may have be
reported as continuous, categorical or dichotomous variables.
Secondary outcomes
1. Participant-reported quality of life measures.
2. Type, dose and frequency of analgesics used.
3. Any adverse effects or harm (hypersensitivity or other
reactions) attributed to antibiotics or analgesics, complications of
surgical treatment or hospitalisations.
Search methods for identification of studies
For the identification of studies included or considered for this
review, we developed a detailed search strategy for each database
searched. These were based on the search strategy developed for
MEDLINE but revised appropriately for each database to take
account of differences in controlled vocabulary and syntax rules.
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The search strategy combined the subject searchwith theCochrane
Highly Sensitive Search Strategy for identifying reports of RCTs
(2008 revision), as published in Box 6.4.c in the Cochrane Hand-
book for Systematic Reviews of Interventions Version 5.1.0 (updated
March 2011) (Higgins 2011). The subject search used a combi-
nation of controlled vocabulary and free text-terms based on the
search strategy for searching MEDLINE. The search of EMBASE
was linked to the Cochrane Oral Health Group filters for identi-
fying RCTs.
Electronic searches
We searched the following databases:
• Cochrane Oral Health Group’s Trials Register (to 1
October 2013);
• Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2013, Issue 9);
• MEDLINE via OVID (1946 to 1 October 2013);
• EMBASE via OVID (1980 to 1 October 2013);
• CINAHL via EBSCO (1980 to 1 October 2013).
SeeAppendix 1 for details of all search strategies used. All databases
were searched from their inception to October 2013 and we ap-
plied no restrictions on language of publication in the electronic
searches.
Searching other resources
We searched the following trials registers for ongoing studies:
• World Health Organization (WHO) International Trials
Registry Platform (to 1 October 2013) (www.who.int/ictrp/en/);
• US National Institutes of Health Trials Registry (
ClinicalTrials.gov) (to 1 October 2013).
We searched for grey literature using the following resources:
• OpenGrey (to 1 October 2013);
• ZETOC Conference Proceedings (1993 to 1 October
2013).
We checked the reference lists of all included and excluded studies
to identify any further trials.
Data collection and analysis
Selection of studies
Two review authors (Anwen Cope (AC) and Mala Mann (MM))
independently assessed the titles and abstracts (where available) of
the articles identified by the search strategy and made decisions
regarding eligibility. Full-text versions were obtain for all articles
being considered for inclusion, as were those with insufficient in-
formation in the title or abstract to make a clear decision. We re-
solved any disagreements by discussion. We excluded studies later
found not to meet the inclusion criteria and recorded them in the
Characteristics of excluded studiestable.
Data extraction and management
We entered study details into the Characteristics of included
studies table. AC and MM independently extracted the outcome
data from the included studies using a standard data extraction
form. The review authors discussed the results and resolved any
disagreements by discussion or with a third review author (Ivor
G Chestnutt (IGC)). In cases where uncertainties persisted, we
contacted the study authors for clarification.
We extracted the following characteristics of the studies.
1. Study methodology: study design, methods of allocation,
method of randomisation, randomisation concealment, blinding,
time of follow-up, loss to follow-up, country conducted in,
number of centres, recruitment period and funding source.
2. Participants: sampling frame, diagnostic criteria, inclusion
criteria, exclusion criteria, number of participants in each group,
baseline group demographics and clinical diagnosis.
3. Intervention: type of antibiotic, dose, frequency and
duration of course. Information about co-interventions, for
example, surgical treatment or analgesia.
4. Outcomes: primary outcomes at 24, 48 and 72 hours and
seven days, and secondary outcomes as previously described
(seePrimary outcomes; Secondary outcomes).
Assessment of risk of bias in included studies
Two review authors (AC and MM) independently assessed the
risk of bias of the included studies and resolved any disagreements
by discussion with a third review author (IGC). We completed a
’Risk of bias’ table for each included study following the recom-
mended methods for assessing the risk of bias in studies included
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). This was a two-part tool addressing specific key
domains including sequence generation, allocation concealment,
blinding, incomplete outcome data, selective outcome reporting
and other bias. We tabulated relevant information describing what
happened, as reported in the study or revealed by correspondence
with the study authors, for each included study, alongwith a judge-
ment of low, high or unclear risk of bias for each individual do-
main.
A summary assessment of the risk of bias of each included study
was made as follows:
• low risk of bias (plausible bias unlikely to seriously alter the
results) if we assessed all key domains to be at low risk of bias;
• unclear risk of bias (plausible bias that raises some doubt
about the results) if we assessed one or more key domains as
unclear;
• high risk of bias (plausible bias that seriously weakens
confidence in the results) if we assessed one or more key domains
to be at high risk of bias.
9Systemic antibiotics for symptomatic apical periodontitis and acute apical abscess in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We completed a ’Risk of bias’ table for each included study. We
also presented the results graphically.
Measures of treatment effect
For dichotomous outcomes, we expressed the estimate of effect
of the intervention as risk ratios (RR) together with 95% con-
fidence intervals (CI). For continuous outcomes (such as mean
VAS scores), we reported mean differences (MD) (or standardised
mean differences (SMD)when different scales measuring the same
concept) and their corresponding 95% CI.
Unit of analysis issues
We anticipate that, by the nature of the outcome variables being
recorded, studies included in future updates may involve repeat
observations. Results from more than one time point for each
study cannot be combined in a standard meta-analysis without a
unit-of-analysis error. Therefore, we assessed outcomes at 24, 48
and 72 hours and seven days postoperatively, as the data allowed.
We included no clustered trials in the review.
Given the nature of the conditions and intervention under review,
it is high unlikely any cross-over trials will be suitable for inclusion
in the future.
In updates, we will consider multi-arm studies for inclusion in
the review, in accordance with recommendations in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
we will combine all relevant experimental groups and considered
them as a single group and compared themwith a combined group
of all the control groups, if present.
Dealing with missing data
We contacted the original investigators in cases of missing data.
Assessment of heterogeneity
We planned to assess heterogeneity using the Chi2 test (P value
< 0.10 regarded as statistically significant). For studies judged as
clinically homogeneous, we test heterogeneity using the I2 statis-
tic, as recommended in the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011). The I2 statistic describes the
percentage of variability in effect estimates that is due to hetero-
geneity rather than sampling error. An I2 of 0% to 40%might not
be important, 30% to 60% may represent moderate heterogene-
ity, 50% to 90% may have substantial heterogeneity and 75% to
100% studies has substantial heterogeneity.
Assessment of reporting biases
We examined within-study selective outcome reporting as a part
of the overall risk of bias assessment and contacted study authors
for clarification.
If there had been at least 10 studies included in a meta-analysis,
we would have assessed between-study reporting bias by creating
a funnel plot of effect estimates against their standard errors. If we
had found asymmetry of the funnel plot by inspection and con-
firmed this by statistical tests, we would have considered possible
explanations and taken into account in the interpretation of the
overall estimate of treatment effects.
Data synthesis
We only carried out meta-analysis where studies of similar com-
parisons, reported similar outcomes, for people with similar clin-
ical conditions. We combined MDs (or SMDs where studies had
used different scales) for continuous outcomes, and combinedRRs
for dichotomous outcomes, using a xed-effect model if there were
only two or three studies, or a random-effects model if there were
four or more studies.
Subgroup analysis and investigation of heterogeneity
We planned to investigate clinical heterogeneity by examining the
following subgroups should sufficient data have been available.
1. Different antibiotic class (e.g. penicillins versus macrolides).
2. The effects of accompanying surgical intervention
(extraction, incision and drainage or endodontic treatment).
Sensitivity analysis
Provided there were sufficient studies for each outcome and in-
tervention, we had planned to undertake sensitivity analysis based
on trials judged to be of low risk of bias.
Presentation of main results
We developed a ’Summary of findings’ table for the primary out-
comes of this reviewusingGRADEPro software, with theGRADE
assessment of the quality of the body of evidence.
R E S U L T S
Description of studies
Results of the search
After de-duplication, electronic searches yielded 625 references.
We identified one additional trial by checking the bibliographies
of the selected trials and reviews (Al-Belasy 2003). After exam-
ination of the titles, and abstracts where available, we excluded
590 references from further analysis. We obtained full-text copies
of the remaining 36 studies, translated them where required, and
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subjected them to further evaluation. At this stage, we excluded
34 studies and recorded their characteristics (Characteristics of
excluded studies; Figure 1).
Figure 1. Study flow diagram.
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Included studies
Two randomised controlled trials (RCTs) satisfied the inclusion
criteria (Fouad 1996;Henry 2001). SeeCharacteristics of included
studies table for further details.
Characteristics of trial designs and settings
Both studies were of parallel group design, one had three arms
(Fouad 1996), and the other had two arms (Henry 2001). Both
studies were conducted at university dental schools in the USA
and were based at a single centre. One study was supported by
a university research fund and the other did not declare funding
sources. Neither study reported sample size calculations.
Characteristics of participants
We included 62 participants in the analysis for this review, with 21
people analysed in Fouad 1996, and 41 people analysed in Henry
2001. Both studies were conducted on otherwise healthy adults.
Participants in one study had a mean age of 36.0 years (standard
deviation (SD) 13.7 years) and had a clinical diagnosis of acute
apical abscess with pulpal necrosis, periapical pain or swelling,
or both (Additional Table 1; Fouad 1996). Participants in the
other study had a mean age of 37 years (SD 16.5 years) in the
penicillin arm and 38 years (SD 18.8 years) in the placebo arm
(Additional Table 2; Henry 2001). All had a symptomatic necrotic
tooth with a periapical radiolucency and no mucosal sinus tract
(Henry 2001).One trial hadmoremale participants (Fouad 1996)
and the other had similar numbers of male and female participants
(Henry 2001). There were no significant differences in the intra-
study baseline characteristics of participants (Additional Table 1;
Additional Table 2).
Characteristics of intervention
Objective 1: systemic antibiotics versus a matched placebo
provided in conjunction with a surgical intervention
In one trial, participants underwent total or partial pulpectomy
under local anaesthesia with temporary restoration at the baseline
visit (Fouad 1996). In the other trial, all participants underwent
total pulpectomy with temporary restoration at the baseline visit
(Henry 2001).
In the study by Fouad 1996, participants in the penicillin group
received oral penicillin (phenoxymethyl) VK 1 g following treat-
ment and then 500 mg, every six hours for seven days. Participants
in the placebo group received an oral matched placebo taken ac-
cording to the same regimen. In the trial by Henry 2001, partic-
ipants in the penicillin group received oral penicillin VK tablets
(Wyeth Laboratories, Philadelphia, PA) 500 mg, every six hours
for seven days and participants in the placebo group received an
oral matched placebo (lactose) taken according to the same regi-
men.
In one trial, all participants also received ibuprofen 600 mg im-
mediately before treatment, on four occasions during the next 24
hours and then as required (Fouad 1996). In the other trial, all
participants received a bottle of ibuprofen 200 mg tablets (Advil,
Whitehall Laboratories, New York, NY) with instructions to take
two tablets every four to six hours as required. Each participant also
received a labelled bottle of paracetamol (acetaminophen) with
codeine (Tylenol #3, McNeil Consumer Products, Fort Washing-
ton, PA) with dosing instructions, to take if two ibuprofen did
not relieve their discomfort. One participant was given Percocet
(oxycodone plus paracetamol (acetaminophen)) instead (Henry
2001).
Objective 2: systemic antibiotics versus a matched placebo
provided without a surgical intervention
We found no studies comparing systemic antibiotics versus a
matched placebo provided without a surgical intervention.
Heterogeneity of interventions
There was heterogeneity with respect to the operative treatment,
doses of antibiotics given to participants in the intervention arms
and type, dose and frequency of analgesics provided to participants
between the two studies.
Characteristics of the outcome measures
Primary outcomes
Both studies reported participant-reported pain. Both utilised a
short ordinal numerical scale graded from 0 to 3. In Fouad 1996,
this score was determined by converting the value from a VAS
on the post-treatment card into a whole number rank. Pain was
measured at the following data points in each study:
• six hours, 12 hours, 24 hours, 48 hours and 72 hours
(Fouad 1996);
• day one, day two, day three, day four, day five, day six, day
seven (Henry 2001).
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Both studies reported participant-reported swelling. In Henry
2001, investigators utilised a short ordinal numerical scale graded
from 0 to 3. In Fouad 1996, increase or decrease in swelling com-
pared with baseline was recorded on a short ordinal numerical
scale graded from 0 to 4. Swelling was measured at the following
data points in each study:
• six hours, 12 hours, 24 hours, 48 hours and 72 hours
(Fouad 1996);
• day one, day two, day three, day four, day five, day six, day
seven (Henry 2001).
One study included percussion pain (Henry 2001). This was mea-
sured on a short ordinal numerical scale graded from 0 to 3.
One study included incidence of endodontic flare-up (Fouad
1996). This was measured dichotomously and was clinician-as-
sessed based on the presence of: no relief or an increase in the
severity of pain; no resolution or an increase in the size of swelling,
fever, trismus or difficulty swallowing; signs of a drug allergy or
any other abnormal symptoms.
Secondary outcomes
One study included the number and type of analgesics required
(Henry 2001). In Fouad 1996, participants recorded whether they
required additional analgesia; however, this information was not
reported and was not available after contacting the investigators.
One study reported adverse effects (Fouad 1996).
Handling of data/data assumptions made in the review
For objective 1, we compared pain and swelling scores at 24, 48
and 72 hours and seven days postoperatively. For the purposes of
the analysis, we made the assumption that the data points from
Henry 2001 (day one, day two and day three) were sufficiently
analogous to those measure in Fouad 1996 to be combined.
Excluded studies
We excluded the majority of references as they were not RCTs.
Other excluded studies did not report relevant health outcomes,
had no placebo control or had other characteristics that did not
satisfy the inclusion criteria (seeCharacteristics of excluded studies
table).
Risk of bias in included studies
The review authors’ judgements about each risk of bias item for
each included study are given in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
Randomisation
We considered both studies to be at low risk of bias for random
sequence generation.
Allocation concealment
We assessed both studies to have adequate concealment of allo-
cation prior to assignment. In Fouad 1996, individuals enrolling
participants into the trial were not aware of the upcoming allo-
cation sequence; envelopes were sequentially numbered, opaque
and sealed; envelopes for the penicillin and placebo groups were
identical in appearance and weight and were only opened after be-
ing assigned to the participant. In Henry 2001, participants were
given sequentially numbered drug containers of identical appear-
ance in accordance with the randomisation sequence produced
prior to the experiment.
Blinding
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We judged both studies to have employed adequate measures to
ensure that active and placebo tablets had identical appearance,
and, therefore, we considered risk of performance bias to be low
for both studies. Similarly, we considered both studies to have low
risk of detection bias as blinding was unlikely to have been broken.
Incomplete outcome data
We considered Fouad 1996 to be at high risk of attrition bias.
Rates of withdrawal were in excess of 20% in across groups, with
higher rates of withdrawal from the placebo than the penicillin
group. We judged differential attrition as likely to be related to
treatment outcomes. In Henry 2001, we were unable to judge risk
of bias due to insufficient reporting of relative attrition rates and
reasons for withdrawal and, therefore, this risk for this domain is
’unclear’.
Selective reporting
We judged one study to be at unclear risk of reporting bias, as
investigators did not report whether the need for additional anal-
gesia differed between the two trial arms, although this informa-
tion was collected on the post-treatment card (Fouad 1996). There
was no evidence of selective reporting within Henry 2001 and all
expected outcomes were presented. We judged this study to be at
low risk of reporting bias.
Other potential sources of bias
We judged both trials to be at low risk of other potential sources
of bias.
Overall risk of bias
One study had high overall risk of bias (Fouad 1996), and one had
unclear risk of bias (Henry 2001) (Figure 2).
Effects of interventions
See: Summary of findings for the main comparison Systemic
antibiotics with a surgical intervention and analgesics for the
management of symptomatic apical periodontitis and acute apical
abscess in adults
Objective 1: systemic antibiotics versus a matched
placebo provided in conjunction with a surgical
intervention
Two studies, one at unclear risk of bias (Henry 2001), and one at
high risk of bias (Fouad 1996), provided data for this comparison.
Both compared oral penicillinVK against amatched placebowhen
provided alongside partial or total pulpectomy for adults with
localised acute apical abscess or symptomatic necrotic tooth in
otherwise healthy adults.
Primary outcomes
Pain
The analysis of participant-reported pain at data points 24, 48 and
72 hours was based on data from two studies (61 participants),
one at high risk of bias (Fouad 1996), and one at unclear risk of
bias (Henry 2001). Analysis of the seven-day time point was based
on data from one study (41 participants) at unclear risk of bias
(Henry 2001).
For the antibiotic group:
• mean difference (MD) at 24 hours -0.03 (95% confidence
interval (CI) -0.53 to 0.47);
• MD at 48 hours 0.32 (95% CI -0.22 to 0.86);
• MD at 72 hours 0.08 (95% CI -0.38 to 0.54);
• MD at seven days -0.05 (95% CI -0.41 to 0.30, P value =
0.77).
Swelling
The analysis of participant-reported swelling at data points 24
hours (61 participants), 48 hours (62 participants) and 72 hours
(61 participants) was based on data from two studies, one at high
risk of bias (Fouad 1996), and one at unclear risk of bias (Henry
2001). Analysis of seven-day time point was based on data from
one study at unclear risk of bias (Henry 2001). Standardised mean
difference (SMD) was used to combine the different scales used
for the 24-, 48- and 72-hour data points.
For the antibiotic group:
• SMD at 24 hours 0.27 (95% CI -0.23 to 0.78). This
converts back into a 36% increase (95% CI 31% decrease to
105% increase) of control mean for antibiotics. Re-expressed
from the SMD into the short ordinal numerical scale used by
Henry 2001. Results should be interpreted with caution since
back-translation of the effect size was based on the results of only
one study.
• SMD at 48 hours 0.04 (95% CI -0.47 to 0.55). This
converts back into a 4% increase (95% CI 49% decrease to 58%
increase) of control mean for antibiotics. Re-expressed from the
SMD into the short ordinal numerical scale used by Henry 2001.
Results should be interpreted with caution since back-translation
of the effect size was based on the results of only one study.
• SMD at 72 hours 0.02 (95% CI -0.49 to 0.52). This
converts back into a 2% increase (95% CI 55% decrease to 59%
increase) of control mean for antibiotics. Re-expressed from the
SMD into the short ordinal numerical scale used by Henry 2001.
Results should be interpreted with caution since back-translation
of the effect size was based on the results of only one study.
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• MD at seven days 0.02 (95% CI -0.28 to 0.32, P value =
0.90)
Percussion pain
The analysis of participant-reported percussion data at data points
24, 48 and 72 hours was based on data from one study (41 par-
ticipants) at unclear risk of bias (Henry 2001).
For the antibiotic group:
• MD at 24 hours -0.32 (95% CI -0.85 to 0.21, P value =
0.24);
• MD at 48 hours 0.09 (95% CI -0.44 to 0.62, P value =
0.74);
• MD at 72 hours 0.05 (95% CI -0.55 to 0.65, P value =
0.87);
• MD at seven days 0.06 (95% CI -0.29 to 0.41, P value =
0.73).
Endodontic flare-up
The analysis of clinician-assessed incidence of endodontic flare-
up over three-day follow-up period was based on data from one
study at high risk of bias (20 participants) (Fouad 1996).
For the antibiotic group:
• risk ratio (RR) of endodontic flare-up 0.27 (95% CI 0.01
to 4.90, P value = 0.37).
Secondary outcomes
Analgesics
The analysis of the number of analgesic tablets required during
the seven-day follow-up period was based on data from one study
(41 participants) at unclear risk of bias (Henry 2001).
For the antibiotic group:
• MD for total number of ibuprofen tablets 1.58 (95% CI -
4.55 to 7.71, P value = 0.62).
• MD for total number of paracetamol (acetaminophen) with
codeine tablets -0.31 (95% CI -3.94 to 3.32, P value = 0.87).
Adverse effects
During the three-day follow-up period in Fouad 1996 (20 par-
ticipants, high risk of bias), one participant in the placebo group
reported diarrhoea and one participant in the antibiotic group re-
ported fatigue and reduced energy postoperatively.
Objective 2: systemic antibiotics versus a matched
placebo provided without a surgical intervention
We found no studies comparing systemic antibiotics versus a
matched placebo provided without a surgical intervention.
D I S C U S S I O N
Summary of main results
The review process identified two studies suitable for inclusion,
both of which assessed the effects of penicillin VK compared with
a matched placebo in adults with localised apical abscess or a
symptomatic necrotic tooth (no signs of spreading infection or
systemic involvement) when provided in conjunction with par-
tial or total pulpectomy conducted under local anaesthesia and
analgesics. There were no statistically significant differences in pri-
mary outcomes (participant-reported pain, swelling or percussion
pain or incidence of endodontic flare-up) or secondary outcomes
(analgesic use or incidence of adverse events) between participants
who had received antibiotics and participants who had received a
matched placebo. We considered this body of evidence (two stud-
ies, one at unclear risk of bias and one at high risk of bias) to be
of very low quality and it should be interpreted with caution.
We found no studies that reported the effects of systemic antibi-
otics versus a matched placebo for symptomatic apical periodonti-
tis when provided in conjunction with a surgical intervention. We
found no studies that reported the effects of systemic antibiotics
versus a matched placebo for symptomatic apical periodontitis or
acute apical abscess when provided without a surgical interven-
tion.
Overall completeness and applicability of
evidence
We employed a comprehensive search strategy and we are confi-
dent that the majority of published trials are included in this re-
view. We made efforts to identify all relevant studies and excluded
no studies due to language.
The two included trials partially addressed the first of the two
objectives (Fouad 1996; Henry 2001), which both investigated
the effect of systemic antibiotics for acute apical abscess or symp-
tomatic necrotic tooth provided in conjunction with total or par-
tial pulpectomy in adults. However, there were no trials that as-
sessed the effects of antibiotics for symptomatic apical periodon-
titis when used in conjunction with a surgical intervention. Fur-
thermore, we found no trials assessing the second objective, which
sought to compare antibiotics and a placebo for symptomatic api-
cal periodontitis or acute apical abscess when provided without a
surgical intervention.
The participants included in the two trials can be considered
broadly representative of people who would consult a dentist due
to an acute apical abscess or symptomatic necrotic tooth who do
not have evidence of spreading infection or systemic involvement
- participants came from a wide age range, were about equal gen-
der mix and the majority had moderate pain at the baseline visit.
However, both the trials excluded participants with co-morbidi-
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ties or who may have been immunocompromised. Therefore, the
results of this review may not be generalisable to a group of people
who may be at higher risk of infection. While future trials should
endeavour to obtain the most representative sample possible, it
is unlikely to be feasible or ethical to conduct placebo-controlled
trials in these groups of people.
One trial excluded participants with signs of spreading infection
and systemic involvement (Fouad 1996), and the other trial in-
cluded only a small number of participants with evidence of se-
vere infections at baseline (Henry 2001). Therefore, the results of
this review may or may not be generalisable to people with severe
swelling or other signs of spreading infection or systemic involve-
ment.
Both of the included studies were conducted at university dental
schools and, in both trials, endodontic treatment was completed
by practitioners who either worked in the Department of En-
dodontics (Fouad 1996), or were senior endodontic graduate stu-
dents (Henry 2001). It would be reasonable to consider that both
groups of practitioners had endodontic skills in excess of those of
an average primary care dentist. The specialist settings in which
the trials were conducted were unlikely to face the time constraints
encountered in routine clinical practice. Therefore, the interven-
tion provided within these studies may only have limited applica-
bility to the treatment routinely provided at emergency appoint-
ments in general dental practice, where treatment decisions are
often dictated by time pressures (Palmer 2000). Therefore, more
trials in a primary care setting would enhance the evidence base
for answering the questions posed by this review.
We found no trials assessing the effect of other surgical inter-
ventions, such as dental extraction or incision and drainage of a
swelling. Since dental extraction is a common treatment for both
symptomatic apical periodontitis and acute apical abscess, and in-
cision and drainage of acute apical abscess is also frequently un-
dertaken, the effects of these interventions could be considered in
future trials.
The outcomes reported by the two trials measured the harms as
well as the benefits of interventions. This is important as antibi-
otics can have adverse effects such as hypersensitivity reactions and
gastrointestinal upset. Many of the outcome measures in the two
included trials were participant-centred, such as pain, percussion
pain and swelling. Since both pain and discomfort are known to
impact an individual’s quality of life (Skevington 1998), future
trials should also consider formally measuring oral health-related
quality of life outcomes to assess the beneficial and harmful effects
of this intervention in more detail.
Quality of the evidence
The quality of the evidence, as summarised in Summary of findings
for the main comparison for the main comparison, was rated as
very low.
Given the considerable number of antibiotics prescribed by den-
tists to adults with acute dental conditions and the problems asso-
ciated with indiscriminate use of antibiotics, the paucity of high-
quality trials evaluating the effects of systemic antibiotics in the
management of symptomatic apical periodontitis and acute apical
abscess is disappointing. Only two studies met the inclusion crite-
ria for this review; we judged one to be at high risk of bias and the
other to be of unclear risk of bias. Both had methodological aws
with respect to attrition bias and the overall quality of evidence was
very low. Furthermore, small group sizes mean that both studies
were likely to lack the statistical power to detect differences be-
tween intervention and placebo groups. Sample size calculations
were not reported in either study. Therefore, caution should be
exercised when interpreting the results presented in this review.
Potential biases in the review process
Two independent review authors extracted data and assessed the
methodological quality of each study, minimising potential bias.
We are confident that the extensive literature search used in this
review has captured relevant literature and minimised the likeli-
hood that we missed any relevant trials.
In the event of incomplete or unclear reporting of trial data, we
contacted the trial authors to obtain any unpublished data or clar-
ification of results. We applied no language or publication restric-
tions in our search.
Despite these efforts, it must be acknowledged that there is a small
possibility that there were additional studies (published and un-
published) that we did not identify. It is possible that additional lit-
erature searches, such as searching non-English language databases
and handsearching relevant journals, would have found additional
studies.
Agreements and disagreements with other
studies or reviews
Systematic reviews of the emergency management of acute api-
cal periodontitis and acute apical abscess in the permanent denti-
tion were published in 2003 (Matthews 2003; Sutherland 2003).
These reviews had wider inclusion criteria and included trials of
analgesics, local pharmacotherapeutics and surgical interventions
in addition to antibiotic trials. Sutherland 2003 concluded that
“the use of antibiotics in the management of AAP [acute apical
periodontitis] is not recommended” and Matthews 2003 recom-
mended that “the use of antibiotics in themanagement of localized
AAA [acute apical abscess] over and above establishing drainage
of the abscess, is not recommended”.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
Based on the current available data, which are of very low qual-
ity, there was insufficient evidence to determine the effects of the
administration of systemic antibiotics to adults with symptomatic
apical periodontitis or acute apical abscess.
Since antibiotic use is recognised as a major contributor to antimi-
crobial resistance, dental professionals should be judicious in their
use of these agents and should refer to evidence-based best practice
guidelines when managing people with acute dental conditions.
Implications for research
Large-scale, adequately powered and well-designed randomised
controlled trials are needed to clarify the effectiveness of systemic
antibiotics in the treatment of symptomatic apical periodontitis
and acute apical abscess. However, all future trials should be care-
fully designed to ensure the potential benefits of providing sys-
temic antibiotics to participants outweigh risks associated with an-
tibiotic usage, both adverse effects and the possible contribution
to antibiotic resistance.
Future studies should consider both utilising validated participant-
and clinician-reported outcome measures, and report results ac-
cording to the Consolidated Standards of Reporting Trials (CON-
SORT) guidelines (www.consort-statement.com/).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Fouad 1996
Methods RCT
Number of centres: 1 (Department of Endodontics, University of Iowa, USA)
Recruitment period: 3.5 years
Design: parallel group 3-arm RCT
Participants Adults presenting for emergency treatment
Group 1 (penicillin)
Mean age 34.92 years (SD17.33 years).Gender: 4women, 8men (1 gender not recorded)
. Mean baseline pain (SD): 2.40 (1.08). Mean baseline swelling (SD): 1.91 (1.51)
Group 2 (placebo)
Mean age 37.17 years (SD 9.40 years). Gender: 6 women, 7men (2 gender not recorded)
. Mean baseline pain (SD): 2.00 (1.10). Mean baseline swelling (SD): 2.00 (1.48)
Included participants had a clinical diagnosis of acute apical abscess with pulpal necrosis
with periapical pain or swelling, or both
Participants were excluded if they had: elevated temperature (above 37.8 ºC (100 ºF)
; malaise; fascial space involvement; allergy to penicillin or cephalosporins; diseases or
medications compromising the immune system; renal failure or any other significant
renal or hepatic impairment; people who had taken antibiotics in the 2-week period
prior to their visit; pregnant or lactating or taking oral contraceptives
Number of participants at randomisation: group 1 = 13; group 2 = 15
Number of participants included in the analysis: group 1 = 10; group 2 = 11
Interventions Endodontic treatment: all participants had the affected tooth treated by total or partial
pulpectomy on day 0. This involved delivery of local anaesthesia, assessment of the tooth,
determination of working length, partial/total cleaning and shaping of the canals with
copious irrigation with 2.6% sodium hypochlorite. Canals were dried and calcium hy-
droxide paste applied and the access cavity temporised with CavitT M (a light-cured tem-
porary sealing compound for temporary restoration of cavities) or IRM® (intermediate
restorative material is a polymer-reinforced zinc oxide-eugenol composition restorative
material designed for intermediate restorations). Some participants also underwent in-
cision and drainage of a localised intraoral swelling, if judged to be clinically indicated
Participants were then assigned to a trial arm:
Group 1: oral penicillin (phenoxymethyl) VK 500 mg, 1 g after endodontic treatment
followed by 500 mg 6-hourly for 7 days
Group 2: oral matched placebo taken according to the same regimen
Group 3: neither medication group
Analgesics: all participants received ibuprofen 600 mg immediately before treatment, 4
times daily for 24 hours and then as needed
Outcomes Primary outcomes
Participants were required to complete a post-treatment card recording their experiences
up to 3 days postoperatively. This card was then returned to the authors via post. Pain
was assessed using a VAS, which was then converted into a short ordinal numerical scale
from 0 to 3: 0 indicated pain of no clinical significance; 1 =mild pain; 2 =moderate pain;
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Fouad 1996 (Continued)
3 = severe pain. Postoperative swelling relief was recorded on a simple categorical scale
(’no swelling’, ’much less’, ’slightly less’, ’same’, ’slightly more’) with participants required
to compare current levels of swelling to those they had experienced preoperatively. The
categorical scale was then given scores from 0 to 4: 0 = no swelling; 1 = significant
reduction in swelling; 2 = slight decrease in swelling; 3 = same size swelling as before; 4
= an increase in the size of swelling
Incidence of flare-up: measured dichotomously and was clinician-assessed based on the
presence of: no relief or an increase in the severity of pain; no resolution or an increase
in the size of swelling, fever, trismus or difficulty swallowing; signs of a drug allergy or
any other abnormal symptoms
Secondary outcomes
Incidence of participant-reported side effects; type and frequency of additional analgesic
medication
Notes Funding source: not stated
Sample size calculation: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “A statistician provided random
numbers” (email from author)
Comment: the participants appeared to be
equally distributed between the penicillin
and placebo groups
Allocation concealment (selection bias) Low risk Author confirmed that there was no way
for the individual(s) enrolling participants
into the trial to know the upcoming allo-
cation sequence; study envelopes were se-
quentially numbered, opaque and sealed;
and study envelopes were only opened once
the participant was enrolled onto the trial
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Author confirmed that the placebo looked
exactly the same as the penicillin tablets
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants recorded the outcome mea-
sures and were blinded to their group as-
signment
Incomplete outcome data (attrition bias)
All outcomes
High risk Following randomisation, there were 13
participants in the penicillin group and
15 in the placebo group. 3 participants in
each group did not return their post-treat-
ment card andwere judged tohave dropped
out. A further 2 participants in the placebo
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Fouad 1996 (Continued)
group were withdrawn (1 at 6 hours and 1
at 24 hours) after returning with symptoms
necessitating further treatment. The miss-
ing data related to these 2 participants was
likely to be related to treatment outcomes
(levels of pain or swelling, or both). Attri-
tion for both arms of the trial was in excess
of 20%, and was higher in the placebo than
the penicillin group
Furthermore, following personal commu-
nication with trial authors, it was identi-
fied that there was incomplete baseline data
(age, gender, baseline pain or swelling) for
5 study participants across the 2 trial arms.
Since the numbers of participants recruited
to each group were low, baseline character-
istics of these 5 individuals may have led
to differences between the penicillin and
placebo groups
Selective reporting (reporting bias) Unclear risk Primary outcome measures reported, 1 sec-
ondary outcome (additional analgesia) not
reported
Other bias Low risk No other sources of bias identified
Henry 2001
Methods RCT
Number of centres: 1 (The Ohio State University College of Dentistry, USA)
Recruitment period: not stated
Design: parallel group 3-arm RCT
Participants Adults presenting for emergency treatment
Group 1 (penicillin)
Mean age 37 years (SD 16.5 years). Gender: 10 women, 9 men. Median baseline pain
(SD): 2.00 (2.00). Median baseline percussion pain (SD): 2.00 (2.00). Median baseline
swelling (SD): 1.00 (2.00)
Group 2 (placebo)
Mean age 38 years (SD 18.8 years). Gender: 10 women, 12 men. Median baseline pain
(SD): 2.00 (1.00). Median baseline percussion pain (SD): 2.00 (2.00). Median baseline
swelling (SD): 0 (1.00)
Included participants had a symptomatic necrotic tooth and actively had spontaneous
pain. To be eligible the affected tooth had to test negative to an electric pulp test (Analytic
Technology Corp., Redmond, WA) and ice; have a periapical radiolucency and not
have had previous endodontic treatment. Included participants were in good health (as
determined by written and verbal history), had not received antibiotics in the 30 days
prior to enrolment to the trial and did not have a probable or actively draining sinus
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Henry 2001 (Continued)
tract
Number of participants at randomisation: not stated in paper, approximately 51 (from
personal communication)
Number of participants included in the analysis: group 1 = 19; group 2 = 22
Interventions Endodontic treatment: all participants underwent total pulpectomy of the affected tooth
on day 0. Canals were prepared using a step-back preparation and K-type files (L.D.
Caulk, Inc., Milford, DE) and irrigated with 2.62% hypochlorite. Following instrumen-
tation, canals were dried and a temporary restoration placed (CavitT M (a light-cured
temporary sealing compound for temporary restoration of cavities))
Participants were then assigned to a trial arm
Group 1: oral penicillin (phenoxymethyl) VK 500 mg, 6-hourly for 7 days
Group 2: oral matched placebo taken according to the same regimen
Analgesics: all participants received a supply of ibuprofen and were advised to take 400
mg (2 x 200 mg tablets) every 4-6 hours, as required. Each participant also received a
labelled bottle of paracetamol (acetaminophen) with codeine (30 mg), which they were
instructed to take 1 or 2 tablets every 4 hours only if 2 ibuprofen tablets did not relieve
their discomfort
Outcomes Primary outcomes
Participant-reported pain, percussion pain and swelling experience at the baseline visit
and upon rising for 7 days after treatment on categorical scales. Participants received a 7-
day diary to record postoperative symptoms upon rising each day. This was returned at
the obturation appointment (typically the end of root canal treatment). Pain was assessed
using a short ordinal numerical scale from0 to 3: 0 = no pain; 1 =mild pain; 2 =moderate
pain; 3 = severe pain. Participants used the same scale to rate pain to percussion (achieve
by tapping the affected tooth with a finger). Swelling was assessed on a similar ordinal
numerical scale from 0 to 3: 0 = no swelling; 1 = mild swelling, a mild puffiness that was
not bothersome; 2 =moderate swelling that caused facial distortion and was bothersome;
3 = a severe swelling that caused serious facial distortion and was very bothersome
Secondary outcomes
The number and type of pain medication taken
Notes Funding source: Graduate Endodontic Student Research Fund and Goldberg Memorial
Fund, Graduate Endodontics, College of Dentistry, The Ohio State University
Sample size calculation: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk
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Henry 2001 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Primary outcome measures were partici-
pant-assessed and it was highly unlikely
blinding was broken
Selective reporting (reporting bias) Low risk
Other bias Low risk
RCT: randomised controlled trial; SD: standard deviation; VAS: visual analogue scale.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Achard 1967 Not an RCT
Al-Belasy 2003 No placebo control
Alves 2000 No placebo control
Angelini 1983 Not an RCT
Anonymous 1968 Not an RCT
Banoczy 1985 Not an RCT
Baratieri 1968 Not an RCT.
Brabant 1968 Not an RCT
Brennan 2006 Not all participants met inclusion criteria for clinical diagnosis. No subgroup data presented
Citoler Gutierrez 1969 Not an RCT
Cumming 1984 Not an RCT
D’Atri 1973 Not an RCT
Davis 1969 Sample included children
De Vries 1974 Not an RCT
Deffez 1992 No placebo control
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(Continued)
Diamantes-Kepiotes 1974 Intervention did not include a systemic antibiotic
Dolci 1982 Not an RCT
Flood 1977 Not an RCT
Gabka 1968 Not an RCT
Groshikov 1970 Not an RCT
Haapasalo 1986 Not an RCT
Hood 1978 Not an RCT
Hooley 1969 Not an RCT
Khosla 1970 Not an RCT
Krzywicki 1975 Not an RCT
Lewis 1986 No placebo control
Lin 2006 Intervention did not include a systemic antibiotic
Lindeboom 2005 Prevention study not fulfilling inclusion criteria
Lorber 1967 Not an RCT
Matijevic 2009 Sample included children
Nowakowska 1974 Not an RCT
Oeda 1985 No placebo control
Ranta 1988 Not all participants met inclusion criteria for clinical diagnosis. No subgroup data presented
Re 1988 No placebo control
RCT: randomised controlled trial.
27Systemic antibiotics for symptomatic apical periodontitis and acute apical abscess in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Pain
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain at 24 hours 2 61 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.53, 0.47]
2 Pain at 48 hours 2 61 Mean Difference (IV, Fixed, 95% CI) 0.32 [-0.22, 0.86]
3 Pain at 72 hours 2 61 Mean Difference (IV, Fixed, 95% CI) 0.08 [-0.38, 0.54]
4 Pain at 7 days 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 2. Swelling
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Swelling at 24 hours 2 62 Std. Mean Difference (IV, Fixed, 95% CI) 0.27 [-0.23, 0.78]
2 Swelling at 48 hours 2 61 Std. Mean Difference (IV, Fixed, 95% CI) 0.04 [-0.47, 0.55]
3 Swelling at 72 hours 2 61 Std. Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.49, 0.52]
4 Swelling at 7 days 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 3. Percussion pain
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Percussion pain at 24 hours 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Percussion pain at 48 hours 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Percussion pain at 72 hours 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Percussion pain at 7 days 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 4. Endodontic flare-up
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of endodontic flare-up 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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Comparison 5. Analgesics
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total number of ibuprofen
tablets
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Total number of paracetamol
(acetaminophen) with codeine
tablets
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Pain, Outcome 1 Pain at 24 hours.
Review: Systemic antibiotics for symptomatic apical periodontitis and acute apical abscess in adults
Comparison: 1 Pain
Outcome: 1 Pain at 24 hours
Study or subgroup Antibiotic Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Fouad 1996 10 0.9 (0.994) 10 1 (1.054) 30.9 % -0.10 [ -1.00, 0.80 ]
Henry 2001 19 1.684 (1.108) 22 1.68 (0.8) 69.1 % 0.00 [ -0.60, 0.60 ]
Total (95% CI) 29 32 100.0 % -0.03 [ -0.53, 0.47 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours [Antibiotic] Favours [Control]
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Analysis 1.2. Comparison 1 Pain, Outcome 2 Pain at 48 hours.
Review: Systemic antibiotics for symptomatic apical periodontitis and acute apical abscess in adults
Comparison: 1 Pain
Outcome: 2 Pain at 48 hours
Study or subgroup Antibiotic Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Fouad 1996 10 0.7 (1.252) 10 0.8 (0.919) 31.7 % -0.10 [ -1.06, 0.86 ]
Henry 2001 19 1.474 (1.264) 22 0.96 (0.785) 68.3 % 0.52 [ -0.14, 1.18 ]
Total (95% CI) 29 32 100.0 % 0.32 [ -0.22, 0.86 ]
Heterogeneity: Chi2 = 1.08, df = 1 (P = 0.30); I2 =8%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours [Antibiotic] Favours [Control]
Analysis 1.3. Comparison 1 Pain, Outcome 3 Pain at 72 hours.
Review: Systemic antibiotics for symptomatic apical periodontitis and acute apical abscess in adults
Comparison: 1 Pain
Outcome: 3 Pain at 72 hours
Study or subgroup Antibiotic Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Fouad 1996 10 0.3 (0.949) 10 0.4 (0.516) 46.6 % -0.10 [ -0.77, 0.57 ]
Henry 2001 19 1.053 (1.177) 22 0.82 (0.795) 53.4 % 0.24 [ -0.39, 0.86 ]
Total (95% CI) 29 32 100.0 % 0.08 [ -0.38, 0.54 ]
Heterogeneity: Chi2 = 0.51, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours [Antibiotic] Favours [Control]
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Analysis 1.4. Comparison 1 Pain, Outcome 4 Pain at 7 days.
Review: Systemic antibiotics for symptomatic apical periodontitis and acute apical abscess in adults
Comparison: 1 Pain
Outcome: 4 Pain at 7 days
Study or subgroup Antibiotic Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henry 2001 19 0.263 (0.653) 22 0.32 (0.477) -0.05 [ -0.41, 0.30 ]
-2 -1 0 1 2
Favours [Antibiotic] Favours [Control]
Analysis 2.1. Comparison 2 Swelling, Outcome 1 Swelling at 24 hours.
Review: Systemic antibiotics for symptomatic apical periodontitis and acute apical abscess in adults
Comparison: 2 Swelling
Outcome: 1 Swelling at 24 hours
Study or subgroup Antibiotic Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Fouad 1996 10 1.5 (1.509) 11 1.82 (1.401) 34.6 % -0.21 [ -1.07, 0.65 ]
Henry 2001 19 1.05 (0.911) 22 0.59 (0.796) 65.4 % 0.53 [ -0.10, 1.16 ]
Total (95% CI) 29 33 100.0 % 0.27 [ -0.23, 0.78 ]
Heterogeneity: Chi2 = 1.87, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours [Antibiotic] Favours [Control]
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Analysis 2.2. Comparison 2 Swelling, Outcome 2 Swelling at 48 hours.
Review: Systemic antibiotics for symptomatic apical periodontitis and acute apical abscess in adults
Comparison: 2 Swelling
Outcome: 2 Swelling at 48 hours
Study or subgroup Antibiotic Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Fouad 1996 10 0.9 (0.876) 10 1.6 (1.647) 32.3 % -0.51 [ -1.40, 0.39 ]
Henry 2001 19 1 (1) 22 0.73 (0.767) 67.7 % 0.30 [ -0.32, 0.92 ]
Total (95% CI) 29 32 100.0 % 0.04 [ -0.47, 0.55 ]
Heterogeneity: Chi2 = 2.13, df = 1 (P = 0.14); I2 =53%
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours [Antibiotic] Favours [Control]
Analysis 2.3. Comparison 2 Swelling, Outcome 3 Swelling at 72 hours.
Review: Systemic antibiotics for symptomatic apical periodontitis and acute apical abscess in adults
Comparison: 2 Swelling
Outcome: 3 Swelling at 72 hours
Study or subgroup Antibiotic Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Fouad 1996 10 0.3 (0.483) 10 0.9 (1.287) 32.0 % -0.59 [ -1.49, 0.31 ]
Henry 2001 19 0.84 (0.958) 22 0.59 (0.666) 68.0 % 0.30 [ -0.32, 0.92 ]
Total (95% CI) 29 32 100.0 % 0.02 [ -0.49, 0.52 ]
Heterogeneity: Chi2 = 2.57, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours [Antibiotic] Favours [Control]
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Analysis 2.4. Comparison 2 Swelling, Outcome 4 Swelling at 7 days.
Review: Systemic antibiotics for symptomatic apical periodontitis and acute apical abscess in adults
Comparison: 2 Swelling
Outcome: 4 Swelling at 7 days
Study or subgroup Antibiotic Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henry 2001 19 0.16 (0.501) 22 0.14 (0.468) 0.02 [ -0.28, 0.32 ]
-2 -1 0 1 2
Favours [Antibiotic] Favours [Control]
Analysis 3.1. Comparison 3 Percussion pain, Outcome 1 Percussion pain at 24 hours.
Review: Systemic antibiotics for symptomatic apical periodontitis and acute apical abscess in adults
Comparison: 3 Percussion pain
Outcome: 1 Percussion pain at 24 hours
Study or subgroup Antibiotic Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henry 2001 19 1.32 (0.82) 22 1.64 (0.902) -0.32 [ -0.85, 0.21 ]
-2 -1 0 1 2
Favours [Antibiotic] Favours [Control]
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Analysis 3.2. Comparison 3 Percussion pain, Outcome 2 Percussion pain at 48 hours.
Review: Systemic antibiotics for symptomatic apical periodontitis and acute apical abscess in adults
Comparison: 3 Percussion pain
Outcome: 2 Percussion pain at 48 hours
Study or subgroup Antibiotic Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henry 2001 19 1.32 (1.003) 22 1.23 (0.685) 0.09 [ -0.44, 0.62 ]
-2 -1 0 1 2
Favours [Antibiotic] Favours [Control]
Analysis 3.3. Comparison 3 Percussion pain, Outcome 3 Percussion pain at 72 hours.
Review: Systemic antibiotics for symptomatic apical periodontitis and acute apical abscess in adults
Comparison: 3 Percussion pain
Outcome: 3 Percussion pain at 72 hours
Study or subgroup Antibiotic Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henry 2001 19 1 (1.054) 22 0.95 (0.899) 0.05 [ -0.55, 0.65 ]
-2 -1 0 1 2
Favours [Antibiotic] Favours [Control]
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Analysis 3.4. Comparison 3 Percussion pain, Outcome 4 Percussion pain at 7 days.
Review: Systemic antibiotics for symptomatic apical periodontitis and acute apical abscess in adults
Comparison: 3 Percussion pain
Outcome: 4 Percussion pain at 7 days
Study or subgroup Antibiotic Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henry 2001 19 0.47 (0.612) 22 0.41 (0.503) 0.06 [ -0.29, 0.41 ]
-2 -1 0 1 2
Favours [Antibiotic] Favours [Control]
Analysis 4.1. Comparison 4 Endodontic flare-up, Outcome 1 Incidence of endodontic flare-up.
Review: Systemic antibiotics for symptomatic apical periodontitis and acute apical abscess in adults
Comparison: 4 Endodontic flare-up
Outcome: 1 Incidence of endodontic flare-up
Study or subgroup Antibiotic Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fouad 1996 0/8 2/11 0.27 [ 0.01, 4.90 ]
0.01 0.1 1 10 100
Favours [Antibiotic] Favours [Control]
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Analysis 5.1. Comparison 5 Analgesics, Outcome 1 Total number of ibuprofen tablets.
Review: Systemic antibiotics for symptomatic apical periodontitis and acute apical abscess in adults
Comparison: 5 Analgesics
Outcome: 1 Total number of ibuprofen tablets
Study or subgroup Antibiotic Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henry 2001 19 10 (9.8) 22 8.42 (10.2) 1.58 [ -4.55, 7.71 ]
-4 -2 0 2 4
Favours [Antibiotic] Favours [Placebo]
Analysis 5.2. Comparison 5 Analgesics, Outcome 2 Total number of paracetamol (acetaminophen) with
codeine tablets.
Review: Systemic antibiotics for symptomatic apical periodontitis and acute apical abscess in adults
Comparison: 5 Analgesics
Outcome: 2 Total number of paracetamol (acetaminophen) with codeine tablets
Study or subgroup Antibiotic Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Henry 2001 19 5.27 (6.03) 22 5.58 (5.77) -0.31 [ -3.94, 3.32 ]
-4 -2 0 2 4
Favours [Antibiotic] Favours [Control]
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A D D I T I O N A L T A B L E S
Table 1. Baseline characteristics for penicillin and placebo trial arms (Fouad 1996)
Trial arm Penicillin (n = 13) Placebo (n = 15) P value
Gender 4W:8M* 6W:7M** -
Mean age in years (SD) 34.92 (17.33) 37.17 (9.40) 0.696
Mean baseline pain (SD) 2.40 (1.08) 2.00 (1.10) 0.410
Mean baseline swelling (SD) 1.91 (1.51) 2.00 (1.48) 0.866
M: men; n: number in group; SD: standard deviation; W: women.
Unpublished data from personal communication.
* Gender of 1 participant not recorded.
** Gender of 2 participants not recorded.
Table 2. Baseline characteristics for penicillin and placebo trial arms (Henry 2001)
Variable Penicillin (n = 19) Placebo (n = 22) P value
Age in years (SD) 37 (16.5) 38 (18.8) 0.884
Gender 10W:9M 10W:12M 0.647
Weight in pounds (SD) 172 (28.4) 170 (41.3) 0.874
Estimated lesion area in mm
(SD)
14.0 (16.5) 24.8 (22.6) 0.105
Median baseline pain (SD) 2.00 (2.00) 2.00 (1.00) 0.463
Median baseline percussion
pain (SD)
2.00 (2.00) 2.00 (2.00) 0.868
Median baseline swelling (SD) 1.00 (2.00) 0 (1.00) 0.097
M: men; n: number in group; SD: standard deviation; W: women.
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A P P E N D I C E S
Appendix 1. Search strategies
Cochrane Oral Health Group’s Trials Register
From October 2013, searches of the Cochrane Oral Health Group’s Trials Register were conducted for this review using the Cochrane
Register of Studies and the search strategy below:
1 ((antibiotic* or anti-biotic* or “anti biotic*” or antibacterial* or anti-bacterial* or “anti bacterial*” or antiinfect* or anti-infect* or
“anti infect*” or antimicrobial* or anti-microbial* or “anti microbial*”):ti,ab) AND (INREGISTER)
2 ((penicillin* or amoxicillin or amoxycillin or co-amoxiclav or ampicillin or erythromycin or clindamycin*):ti,ab) AND (INREGIS-
TER)
3 ((doxycycline* or metronidazole or azithromycin or co-amoxiclav or oxytetracycline or cefalexin or cephalexin or cefradine or
cephradine or clarithromycin):ti,ab) AND (INREGISTER)
4 ((tetracycline or actimoxi or amoxicilline or amoxil or BRL-2333 or clamoxyl or hydroxyampicillin or penamox or polymox or trimox
or wymox or amoxi-clav or amoxi-clavulanate or augmentin or BRL-25000):ti,ab) AND (INREGISTER)
5 ((clavulanate or clavulin or coamoxiclav or spektramox or synulox or phenoxymethylpenicillin or apocillin or beromycin or berromycin
or betapen or fenoxymethylpenicillin or “Pen VK” or “v-cillin K” or vegacillin or clont or danizol ):ti,ab) AND (INREGISTER)
6 ((trichazol* or trichapol or trivazol or satric or metrogyl or flagyl or gineflavir or metrodzhil or nidagyl or chlolincocin or chlorlincocin
or cleocin or “dalacin c”):ti,ab) AND (INREGISTER)
7 (#1 or #2 or #3 or #4 or #5 or #6) AND (INREGISTER)
8 ((abscess* or periapical or peri-apical or “peri apical”):ti,ab) AND (INREGISTER)
9 (#7 and #8) AND (INREGISTER)
A previous search of the Cochrane Oral Health Group’s Trials Register was conducted in June 2012, using the Procite software and the
search strategy below:
((antibiotic* or anti-biotic* or “anti biotic*” or antibacterial* or anti-bacterial* or “anti bacterial*” or antiinfect* or anti-infect* or
“anti infect*” or antimicrobial* or anti-microbial* or “anti microbial*” or penicillin* or amoxicillin or amoxycillin or co-amoxiclav or
ampicillin or erythromycin or clindamycin* or doxycycline* or metronidazole or azithromycin or co-amoxiclav or oxytetracycline or
cefalexin or cephalexin or cefradine or cephradine or clarithromycin or tetracycline or actimoxi or amoxicilline or amoxil or BRL-2333
or clamoxyl or hydroxyampicillin or penamox or polymox or trimox or wymox or amoxi-clav or amoxi-clavulanate or augmentin or
BRL-25000 or clavulanate or clavulin or coamoxiclav or spektramox or synulox or phenoxymethylpenicillin or apocillin or beromycin
or berromycin or betapen or fenoxymethylpenicillin or “Pen VK” or “v-cillin K” or vegacillin or clont or danizol or trichazol* or
trichapol or trivazol or satric or metrogyl or flagyl or gineflavir or metrodzhil or nidagyl or chlolincocin or chlorlincocin or cleocin or
“dalacin c”) AND abscess* or periapical or peri-apical or “peri apical”))
Cochrane Central Register of Controlled Trials (CENTRAL)
#1 MeSH descriptor Anti-Infective Agents explode all trees
#2 MeSH descriptor Penicillins explode all trees
#3 (antibiotic* in All Text or anti-biotic* in All Text or “anti biotic*” in All Text)
#4 (antibacterial* in All Text or anti-bacterial* in All Text or “anti bacterial*” in All Text)
#5 (antiinfect* in All Text or anti-infect* in All Text or “anti infect*” in All Text)
#6 (antimicrobial* in All Text or anti-microbial* in All Text or “anti microbial*” in All Text)
#7 (penicillin* in All Text or amoxicillin in All Text or amoxycillin in All Text or co-amoxiclav in All Text or ampicillin in All Text or
erythromycin in All Text or clindamycin* in All Text or doxycycline* in All Text or metronidazole in All Text or azithromycin in All
Text or co-amoxiclav in All Text or oxytetracycline in All Text or cefalexin in All Text or cephalexin in All Text or cefradine in All Text
or cephradine in All Text or clarithromycin in All Text or tetracycline in All Text)
#8 (actimoxi in All Text or amoxicilline in All Text or amoxil in All Text or BRL-2333 in All Text or clamoxyl in All Text or
hydroxyampicillin in All Text or penamox in All Text or polymox in All Text or trimox in All Text or wymox in All Text or amoxi-clav
in All Text or amoxi-clavulanate in All Text or augmentin in All Text or BRL-25000 in All Text or clavulanate in All Text or clavulin
in All Text or coamoxiclav in All Text or spektramox in All Text or synulox in All Text)
#9 (phenoxymethylpenicillin in All Text or apocillin in All Text or beromycin in All Text or berromycin in All Text or betapen in All
Text or fenoxymethylpenicillin in All Text or “Pen VK” in All Text or “v-cillin K” in All Text or vegacillin in All Text)
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#10 (clont in All Text or danizol in All Text or trichazol* in All Text or trichapol in All Text or trivazol in All Text or satric in All Text
or metrogyl in All Text or flagyl in All Text or gineflavir in All Text or metrodzhil in All Text or nidagyl in All Text)
#11 (chlolincocin in All Text or chlorlincocin in All Text or cleocin in All Text or “dalacin c” in All Text)
#12 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11)
#13 MeSH descriptor Periapical diseases explode all trees
#14 (dental* in All Text near/5 absces* in All Text)
#15 ( (tooth in All Text near/5 absces* in All Text) or (teeth in All Text near/5 absces* in All Text) )
#16 ( (periapical in All Text near/5 absces* in All Text) or (peri-apical in All Text near/5 absces* in All Text) or (apical in All Text near/
5 absces* in All Text) )
#17 ( (periapical in All Text near/5 periodont* in All Text) or (peri-apical in All Text near/5 periodont* in All Text) or (apical in All
Text near/5 periodont* in All Text) )
#18 ( (periapical in All Text near/5 inflam* in All Text) or (peri-apical in All Text near/5 inflam* in All Text) or (apical in All Text near/
5 inflam* in All Text) )
#19 ( (periapical in All Text near/5 infect* in All Text) or (peri-apical in All Text near/5 infect* in All Text) or (apical in All Text near/
5 infect* in All Text) )
#20 ( (dentoalveol* in All Text near/5 absces* in All Text) or (dento-alveol* in All Text near/5 absces* in All Text) or (alveol* in All
Text near/5 absces* in All Text) )
#21 ( (periradicular in All Text near/5 absces* in All Text) or (peri-radicular in All Text near/5 absces* in All Text) or (radicular in All
Text near/5 absces* in All Text) )
#22 (#13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21)
#23 (#12 and #22)
MEDLINE via OVID
1. exp Anti-Infective Agents/
2. exp Penicillins/
3. (antibiotic$ or anti-biotic$ or “anti biotic$”).tw.
4. (antibacterial$ or anti-bacterial$ or “anti bacterial$”).tw.
5. (antiinfect$ or anti-infect$ or “anti infect$”).tw.
6. (antimicrobial$ or anti-microbial$ or “anti microbial$”).tw.
7. (penicillin$ or amox?cillin or co-amoxiclav or ampicillin or erythromycin or clindamycin$ or doxycycline$ or metronidazole or
azithromycin or co-amoxiclav or oxytetracycline or cefalexin or cephalexin or cefradine or cephradine or clarithromycin or tetracy-
cline).tw.
8. (actimoxi or amoxicilline or amoxil or BRL-2333 or clamoxyl or hydroxyampicillin or penamox or polymox or trimox or wymox or
amoxi-clav or amoxi-clavulanate or augmentin or BRL-25000 or clavulanate or clavulin or coamoxiclav or spektramox or synulox).tw.
9. (phenoxymethylpenicillin or apocillin or beromycin or berromycin or betapen or fenoxymethylpenicillin or “Pen VK” or “v-cillin
K” or vegacillin).tw.
10. (clont or danizol or trichazol$ or trichapol or trivazol or satric or metrogyl or flagyl or gineflavir or metrodzhil or nidagyl).tw.
11. (chlolincocin or chlorlincocin or cleocin or “dalacin c”).tw.
12. or/1-11
13. exp Periapical diseases/
14. (dental$ adj5 absces$).tw.
15. ((tooth or teeth) adj5 absces$).tw.
16. ((periapical adj5 absces$) or (peri-apical adj5 absces$) or (apical adj5 absces$)).tw.
17. ((periapical adj5 periodont$) or (peri-apical adj5 periodont$) or (apical adj5 periodont$)).tw.
18. ((periapical adj5 inflam$) or (peri-apical adj5 inflam$) or (apical adj5 inflam$)).tw.
19. ((periapical adj5 infect$) or (peri-apical adj5 infect$) or (apical adj5 infect$)).tw.
20. ((dentoalveol$ adj5 absces$) or (dento-alveol$ adj5 absces$) or (alveol$ adj5 absces$)).tw.
21. ((periradicular adj5 absces$) or (peri-radicular adj5 absces$) or (radicular adj5 absces$)).tw.
22. or/13-21
23. 12 and 22
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The above subject search was linked to the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials in
MEDLINE: sensitivity maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of theCochrane
Handbook for Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011) (Higgins 2011).
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. or/1-8
10. exp animals/ not humans.sh.
11. 9 not 10
EMBASE via OVID
1. exp Antiinfective agent/
2. exp Penicillin derivate/
3. (antibiotic$ or anti-biotic$ or “anti biotic$”).tw.
4. (antibacterial$ or anti-bacterial$ or “anti bacterial$”).tw.
5. (antiinfect$ or anti-infect$ or “anti infect$”).tw.
6. (antimicrobial$ or anti-microbial$ or “anti microbial$”).tw.
7. (penicillin$ or amox?cillin or co-amoxiclav or ampicillin or erythromycin or clindamycin$ or doxycycline$ or metronidazole or
azithromycin or co-amoxiclav or oxytetracycline or cefalexin or cephalexin or cefradine or cephradine or clarithromycin or tetracy-
cline).tw.
8. (actimoxi or amoxicilline or amoxil or BRL-2333 or clamoxyl or hydroxyampicillin or penamox or polymox or trimox or wymox or
amoxi-clav or amoxi-clavulanate or augmentin or BRL-25000 or clavulanate or clavulin or coamoxiclav or spektramox or synulox).tw.
9. (phenoxymethylpenicillin or apocillin or beromycin or berromycin or betapen or fenoxymethylpenicillin or “Pen VK” or “v-cillin
K” or vegacillin).tw.
10. (clont or danizol or trichazol$ or trichapol or trivazol or satric or metrogyl or flagyl or gineflavir or metrodzhil or nidagyl).tw.
11. (chlolincocin or chlorlincocin or cleocin or “dalacin c”).tw.
12. or/1-11
13. exp Tooth periapical disease/
14. (dental$ adj5 absces$).tw.
15. ((tooth or teeth) adj5 absces$).tw.
16. ((periapical adj5 absces$) or (peri-apical adj5 absces$) or (apical adj5 absces$)).tw.
17. ((periapical adj5 periodont$) or (peri-apical adj5 periodont$) or (apical adj5 periodont$)).tw.
18. ((periapical adj5 inflam$) or (peri-apical adj5 inflam$) or (apical adj5 inflam$)).tw.
19. ((periapical adj5 infect$) or (peri-apical adj5 infect$) or (apical adj5 infect$)).tw.
20. ((dentoalveol$ adj5 absces$) or (dento-alveol$ adj5 absces$) or (alveol$ adj5 absces$)).tw.
21. ((periradicular adj5 absces$) or (peri-radicular adj5 absces$) or (radicular adj5 absces$)).tw.
22. or/13-21
23. 12 and 22
The above subject search was linked to the Cochrane Oral Health Group filter for identifying randomised controlled trials in EMBASE
via OVID:
1. random$.ti,ab.
2. factorial$.ti,ab.
3. (crossover$ or cross over$ or cross-over$).ti,ab.
4. placebo$.ti,ab.
5. (doubl$ adj blind$).ti,ab.
6. (singl$ adj blind$).ti,ab.
7. assign$.ti,ab.
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8. allocat$.ti,ab.
9. volunteer$.ti,ab.
10. CROSSOVER PROCEDURE.sh.
11. DOUBLE-BLIND PROCEDURE.sh.
12. RANDOMIZED CONTROLLED TRIAL.sh.
13. SINGLE BLIND PROCEDURE.sh.
14. or/1-13
15. (exp animal/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans).ti.)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• We have made a minor alteration to the objectives to specify the difference between antibiotics provided with a surgical
intervention and those without.
• We used a fixed-effect model in the meta-analysis not a random-effects model as specified by the protocol. This was because
fewer trials were suitable for inclusion than we initially anticipated.
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